{rfName}
Ac

Citations

10

Altmetrics

Analysis of institutional authors

Sanchez, Jose Luis AndreuAuthor

Share

October 21, 2024
Publications
>
Article
No

Actualización del Documento de Consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas y sintéticas dirigidas en la artritis reumatoide

Publicated to: Reumatologia Clinica. 20 (8): 423-439 - 2024-10-01 20(8), DOI: 10.1016/j.reuma.2024.05.007

Authors:

Alvaro, JMAG; Fontecha, PDD; Sánchez, JLA; Criado, AB; Cáliz, RC; Fernández, IC; Corominas, H; Puerta, JAG; Arija, SM; Vázquez, NM; García, AO; Rodríguez, CP; Fernández, LS; Molina, JT
[+]

Affiliations

Complexo Hosp Univ A Coruna, Serv Reumatol, La Coruna, Spain - Author
Hosp Clin Barcelona, Serv Reumatol, Barcelona, Spain - Author
Hosp Gen Univ Gregorio Maranon, Serv Reumatol, IiSGM, Madrid, Spain - Author
Hosp Gregorio Maranon, Inst Invest Sanitaria Gregorio Maranon, Serv Reumatol, Dr Esquerdo,46, E-28007 Madrid, Spain - Author
Hosp Maig, Barcelona, Spain - Author
Hosp Reg Univ Malaga, UGC Reumatol, Malaga, Spain - Author
Hosp Univ Guadalajara, Serv Reumatol, Madrid, Spain - Author
Hosp Univ La Paz, Serv Reumatol, Madrid, Spain - Author
Hosp Univ La Princesa, Inst Invest Sanitaria, Serv Reumatol, Madrid, Spain - Author
Hosp Univ Puerta de Hierro Majadahonda, Serv Reumatol, Madrid, Spain - Author
Hosp Univ Santa Creu & St Pau, Serv Reumatol, Barcelona, Spain - Author
Hosp Virgen de las Nieves, Secc Reumatol, Granada, Spain - Author
Inst Invest Biomed Malaga IBIMA Plataforma Bionand, Malaga, Spain - Author
Inst Invest Biomed Malaga IBIMA Plataforma Bionand, UGC Reumatol, Malaga, Spain - Author
Soc Espanola Reumatol, Unidad Invest, Madrid, Spain - Author
Univ Alcala De Henares, Dept Med, Madrid, Spain - Author
Univ Autonoma Madrid, Fac Med, Madrid, Spain - Author
Univ Complutense Madrid, Dept Med, Madrid, Spain - Author
Univ Complutense Madrid, Madrid, Spain - Author
Univ Malaga, Dept Med, Malaga, Spain - Author
Univ Malaga, Hosp Reg Univ Malaga, Malaga, Spain - Author
See more

Abstract

Objective: To update the consensus document of the Spanish Society of Rheumatology (SER) regarding the use of targeted biological and synthetic therapies in rheumatoid arthritis (RA) with the aim of assisting clinicians in their therapeutic decisions. Methods: A panel of 13 experts was assembled through an open call by SER. We employed a mixed adaptation-elaboration-update methodology starting from the 2015 Consensus Document of the Spanish Society of Rheumatology on the use of biological therapies in RA. Starting with systematic reviews (SR) of recommendations from EULAR 2019, American College of Rheumatology 2021, and GUIPCAR 2017, we updated the search strategies for the PICO questions of GUIPCAR. An additional SR was conducted on demyelinating disease in relation to targeted biological and synthetic therapies. Following the analysis of evidence by different panelists, consensus on the wording and level of agreement for each recommendation was reached in a face-to-face meeting. Results: The panel established 5 general principles and 15 recommendations on the management of RA. These encompassed crucial aspects such as the importance of early treatment, therapeutic goals in RA, monitoring frequency, the use of glucocorticoids, the application of conventional synthetic disease- modifying antirheumatic drugs (csDMARDs), biological DMARDs (bDMARDs), and targeted synthetic DMARDs. Additionally, recommendations on dose reduction of these drugs in stable patients were included. This update also features recommendations on the use of bDMARDs and Janus Kinase inhibitors in some specific clinical situations, such as patients with lung disease, a history of cancer, heart failure, or demyelinating disease. Conclusions: This update provides recommendations on key aspects in the management of RA using targeted biological and synthetic therapies. (c) 2024 Elsevier Espana, S.L.U. and Sociedad Espanola de Reumatolog & imath;a y Colegio Mexicano de Reumatolog & imath;a. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
[+]

Keywords

Adalimumab plus methotrexateBiological drugsBreast-cancer recurrenceDifferent treatment strategiesDouble-blinHealth-care costsJanus kinase inhibitorsJanus kinaseinhibitorLow disease-activityModifying antirheumatic drugsNecrosis-factor inhibitorsRapid radiographic progressionRheumatoid arthritisTreat-to-target

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Reumatologia Clinica, and although the journal is classified in the quartile Q4 (Agencia WoS (JCR)), its regional focus and specialization in Rheumatology, give it significant recognition in a specific niche of scientific knowledge at an international level.

Independientemente del impacto esperado determinado por el canal de difusión, es importante destacar el impacto real observado de la propia aportación.

Según las diferentes agencias de indexación, el número de citas acumuladas por esta publicación hasta la fecha 2026-04-01:

  • WoS: 3
[+]

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2026-04-01:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 10.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 15 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 54.
  • The number of mentions on the social network X (formerly Twitter): 67 (Altmetric).
  • The number of mentions in news outlets: 1 (Altmetric).
[+]